Oncolytics announces issuance of 2nd European patent.
"This patent is consistent with our strategy to continue to expand and strengthen our portfolio of intellectual property worldwide," said Dr. Matt Coffey, Chief Scientific Officer for Oncolytics. "Along with our clinical trial and collaborative research programs in Europe, the United States and Canada, these patents are a key component of our development strategy for REOLYSIN."
Oncolytics is a biotechnology company focused on the development of REOLYSIN, its proprietary formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics' researchers have demonstrated that the reovirus is able to selectively kill cancer cells and, in vitro, kill human cancer cells that are derived from many types of cancer including breast, prostate, pancreatic, bladder and brain tumours, and have also demonstrated successful cancer treatment results in a number of animal models. Phase I clinical trial results have indicated that REOLYSIN was well tolerated and that the reovirus demonstrated activity in tumours injected with REOLYSIN.
Oncolytics Biotech, Inc.
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||Aug 1, 2005|
|Previous Article:||Sigma-Aldrich licenses fundamental RNAi patent estate from Alnylam.|
|Next Article:||Alfred E. Mann Foundation obtains United States patent.|